NovoCure Ltd (NVCR)

↓ Download CSV

CIK 0001645113 · Nasdaq · Surgical & Medical Instruments & Apparatus

  • Sector Manufacturing
  • Fiscal year ends Dec 31

In fiscal 2025, NovoCure Ltd reported revenue of $655.35M, up 8.3% from the prior year. The company ran a net loss, with a net margin of -20.8% and a gross margin of 74.5%. It held $804.33M in total assets against $463.86M in total liabilities.

Key ratios (FY2025)

74.5%
Gross margin
-23.5%
Operating margin
-20.8%
Net margin
-40.0%
Return on equity
+8.3%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019201820172016
Revenue$655.35M$605.22M$509.34M$537.84M$535.03M$494.37M$351.32M$248.07M$177.03M$82.89M
Cost of Revenue$166.88M$137.18M$128.28M$114.87M$114.88M$106.50M$88.61M$80.05M$55.61M$39.87M
Gross Profit$488.47M$468.04M$381.06M$422.97M$420.15M$387.87M$262.71M$168.02M$121.42M$36.61M
Operating Income-$153.80M-$170.50M-$232.87M-$89.52M-$44.33M$30.40M-$914.0K-$33.67M-$39.33M-$115.32M
Net Income-$136.23M-$168.63M-$207.04M-$92.53M-$58.35M$19.81M-$7.23M-$63.56M-$61.66M-$131.84M
EPS (Diluted)$-1.22$-1.56$-1.95$-0.88$-0.56$0.18$-0.07$-0.69
Total Assets$804.33M$1.24B$1.15B$1.19B$1.14B$1.05B$479.45M$339.79M$265.30M$282.08M
Total Liabilities$463.86M$880.61M$783.63M$750.48M$729.00M$575.46M$261.66M$227.53M$151.73M$139.74M
Shareholders' Equity$340.47M$360.18M$362.50M$441.17M$410.49M$476.53M$217.79M$112.26M$113.56M$142.34M
Cash & Equivalents$93.55M$163.77M$240.82M$115.33M$208.80M$234.67M$177.32M$140.62M$78.59M$99.78M
Operating Cash Flow-$49.03M-$26.37M-$73.34M$30.79M$82.76M$99.15M$26.62M-$1.86M-$33.13M-$107.59M
Capital Expenditures$26.65M$42.85M$27.09M$21.36M$24.17M$14.97M$10.48M$6.71M$7.37M$5.67M
Shares Outstanding112.49M108.52M107.08M105.05M103.97M102.33M99.53M93.25M89.48M87.07M